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The pivotal role played by antigen in the clonal selection of B cells for initial
participation in an immune response is well established. Antigen selective mech-
anisms ensure that antigen-binding antibodies are produced during all stages of
the immune response. However, antibodies that lack specificity for the immu-
nogen might also be produced during the course of an antigen-driven immune
response. It has been suggested that, through idiotype-antiidiotype network
interactions within the immune system, production of antibodies that lack spec-
ificity for the immunogen but that share idiotopes with antigen-binding antibod-
ies could result (1). In addition, data obtained by a number of investigators
suggest that somatic mutation of antibody V region genes occurs at a rate of
10-s/basepair/cell division in B cells participating in an immune response (2, 3).
One outcome of such V region structural alteration could be antibodies that
lack, or have drastically reduced affinity for the immunogen . We sought to
identify and characterize some of the antibody by-products of the antigen-driven
immune response that are expected to be created by the mechanisms described
above.
Materials and Methods
Immunizations and Hybridoma Formation and Characterization.
￿
A/J mice were immu-
nized intraperitoneally with 200,ugp-azophenylarsonate-keyhole limpet hemocyanin (Ars-
KLH)' emulsified in complete Freund's adjuvant (CFA) and either killed 13 or 21 d later
or boosted with 150,ug of Ars-KLH in saline intraperitoneally 30 d later and sacrified 3
d after boost. Total spleen cells were fused to Sp2/0 and hybridomas were selected as
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' Abbreviations used in this paper:
￿
Ars-KLH, p-azophenylarsonate-keyhole limpet hemocyanin;
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described (4). The fusion products were screened for V crossreactive idiotype (VHIdcR)-
expressing hybridomas using a technique that detects VHIdcR mRNA in whole cell lysates
immobilized on nitrocellulose filters (4). Supernatants from cultures containing VHIdcR-
expressing hybridomas were tested for the presence of Ars-binding antibodies using an
Ars-BSA plate-binding RIA. Supernatants from hybridomas that did not produce Ars-
binding antibodies were then tested for the presence of antibodies bearing idiotopes
characteristic of canonical combination (see text)-encoded antibodies that are recognized
by four different antiidiotypic reagents (rabbit anti-crossreactive idiotype [CRI], mAb
AD8, mAb 50, and rabbit anti-45-49 [see references 5 and 6 for a detailed description
of the specificities of these reagents]). Solid-phase competition RIA (using 36-65 as the
labeled ligand) were used for this purpose.
Nucleic Acid and Protein Sequencing Analyses.
￿
Three strategies were used to determine
the primary V region structure of antibodies: amino acid sequencing, direct antibody
mRNA sequencing using oligonucleotide primers (7), and sequencing by base-specific
chemical cleavage of V region cDNAs the synthesis of which was primed using s2P end-
labeled oligonucleotides (8). For amino acid sequencing, hybridoma cell lines were grown
as ascites tumors and antibodies were purified from ascites, and heavy and light chains
were separated as previously described (9). The hVH65-110 antibody (see text) had a
high enough affinity for Ars to be purified on Ars-KLHSepharose columns. The hVH65-
107 antibody (see text) would not bind to such columns, and was purified by chromatog-
raphy on DEAE-cellulose. Light chain tryptophan peptides were prepared as described
previously (10), and details of Edman degradation are as reported (11). Oligonucleotide
primers that hybridize specifically to the 5' ends of the C,3, the C,1, and the CK genes, as
well as two primers that hybridize specifically to sites within the VHIdcR and VKIdcR genes
were used.
Results
In the advanced stages of the anti-Ars response (days 13-21 of the primary
and day 3 of the secondary) a single combination of V region gene segments (the
canonical combination) encodes a majority of the antibodies expressed by the
responding B cell population (12). This canonical combination is composed of
VHIdcR, a D segment apparently partially derived from the strain A DFL16.1
locus (13) and termed Dc', the JH2 gene segment, a member of the V.10 gene
segment family termed VKIdcR and the JK1 gene segment (12). Despite this
homogeneity of combinatorial diversity, a variety of different Ars-binding V
region structures are nevertheless expressed during the late stages of the anti-
Ars response due to extensive alteration of these segments via somatic mutation
(12).
Hybridomas were constructed from the spleen cells of Ars-KLH-immunized
A/J mice, and were screened only for expression of VHIdcR mRNA (4). Mice
undergoing a secondary or primary anti-Ars response were used. The times after
immunization used (see Materials and Methods) were chosen to provide points
representing different phases of the maturation of the response. The antibodies
produced by VHIdcR-expressing hybridomas were subsequently screened for Ars-
binding activity.
We routinely observe that a significant fraction of the hybridomas that express
VHIdcR and are isolated from Ars-KLH immunized mice do not express either
Ars, Ars-KLH, or KLH-binding antibodies (T. Manser, unpublished data). Table
I shows that a large fraction of the VHIdcR-expressing hybridomas we isolated
produce antibodies that do not bind to Ars-BSA. Some of these hybridomas are
probably the result of fusion events between unactivated B cells and the myeloma1458
￿
BY-PRODUCTS OF THE IMMUNE RESPONSE
TABLE I
Characteristics ofHybridomas Isolatedfrom Ars-KLH-immunized mice.
The total number of hybridomas isolated at various times after immunization are
indicated (total hybridomas) as are the numbersof thesehybridomas that express RNA
homologous to VHIdcR (VH mRNA+), antibodies that do not bind detectably to Ars (V.
mRNA', Ars),andantibodies that bear idiotypic determinants characteristic ofVHIdcR-
encoded Ars-binding antibodies (VH mRNA', Ars", Id'). Four antiidiotypic reagents
were used: tworabbit polyclonal antisera (anti-CRIandanti-45-49) andtwoantiidiotypic
mAb (ADS and 5Ci). The specificities of these antiidiotypic antibodies have been
describedelsewhere (see Materialsand Methods). One hybridoma (hVH65-110) from
the day 13 fusion bore an idiotypic determinant detected by the 50 mAb, and one
antibody (hVH65-107) from the day 21 fusion bore idiotypic determinants recognized
by the rabbit anti-45-49 polyclonal reagent.
fusion partner. To avoid the analysis ofsuch cell lines we examined only V,,Idc'z-
expressing hybridomas that produced Ars-nonbinding antibodies bearing idi-
otypic determinants characteristic of Ars-binding VHIdcR-encoded V regions.
Because the precursor frequency of idiotype-bearing VHIdcR-encoded V regions
in the naive B cell population is very low (14, 15), we would not expect to isolate
hybridomas expressing such V regions as a result of fusion with unactivated B
cells. Two cell lines expressing VHIdcR and idiotype-positive Ars-nonbinding
antibodies were isolated 13 and 21 d after primary immunization. These hybri-
domas, designated hVH65-107 and hVH65-110, express IgGI and IgG3 anti-
bodies, respectively. Synthesis ofantibodies ofthe IgG classis a property thought
to be dependent on B cell activation (16), and suggests that these hybridomas
were derived from B cells that were activated during the anti-Ars response. The
frequency of this type of hybridoma among VHIdcR-expressing hybridomas
isolated from the primary response was very low (3-4%), and none of the
secondary hybridomas producing Ars-nonbinding antibodies expressed idiotype-
positive V regions. The idiotypic crossreactivity ofthe hVH65-107 and hVH65-
110 V regions was not extensive, as each reacted with only one of the four
antiidiotypic reagents tested (see Table 1).
Theprimarystructures ofthe V regionsexpressedby hVH65-107 and hVH65-
110 were determined and are shown in Figs. 1 and 2. The amino acid and
nucleotide sequences are compared to the sequence of 36-65, an Ars-binding
antibody encoded by the canonical combination ofV gene segments in germline
form. From this comparison, and Southern blotting analysis of the rearranged
V and VK genes in hybridoma DNAs using VHIdcR and VHIdcR probes (data not
shown) we conclude that the V regions expressed by hVH65-107 and hVH65-
110 are encoded by the canonical combination of gene segments but have been
extensively altered by somatic mutation.
Figs. I and 2 also show that both antibodies contain serine at VH junctional
position 99 and arginine at VKjunctional position 96, twojunctional amino acids
that have been shown to be important for Ars-binding activity in canonical
Time of fusion Total
hybridomas VH mRNA'
VH
mRNA',
Ars
VH
mRNA
Ars, Id
Day 13 of primary response 1,700 31 11 1
Day 21 ofprimaryresponse 1,400 25 18 1
Day 3 of secondary response 1,450 36 15 0VH SEQUENCES
D * * V * r * I * w */
MANSER ET AL .
N
1459
10
￿
20
36-65 E V Q L Q Q S G A E L V R A G S S V K M S C K A S G
GAG GTT CAG CTT CAG CAG TCT GGA OCT GAG CTG GIG AGG GCT GGG TCC ICA GIG AAG ATG TCC TGC AAG GCT TCT GGA
hVH65-110
￿
___ __G
￿
-_A ___ ___ __- _N_ ___ ___ ___ -__ ___ _-_ ___ __- ___ _N_ ___ ___
* w w * * * w * w x w w r * * w x w r * x x w * w r
hVH65-107
￿
_-_ _-_ ___ ___ ___ ___ ___ __- ___ _-_ -__ ___ -__ ___ ___ ___ ___ ___ _-_ ___ ---
* I w x x w * * x w x w r * w w w * * w x w * w w w
-30_____CDR1--_____
￿
40
￿
_50___________-___--___
Y T F T S Y G I N W V K Q R P G Q G L E W I G Y I N P G N
TAT ACA TIC ACA AGC TAC GGT ATA AAC TGG GIG AAA CAG AGG CCT GGA CAG GGC CTG GAA TGG ATT GGA TAT ATT AAT CCT GGA AAT
GGT TAT ACT AAG TAC AAT GAG AAG TIC AAG GGC AAG ACC ACA CTG ACT GTA GAC AAA TCC TCC AGC ACA GCC TAC ATG CAG CTC AGA
___ ___ _T_ r__ A-- ___ ___ -- A ___ ___ ___ ___ -__ ___ ___ -__ ___ ___
￿
--r . __- ___ ___ ___ ___ -__ ___ ___ ___ ---
------------------------CDR3-___-___-______-_______
90
￿
____100_____D REGION-----------
￿
------------110____
S L T S E D S A V Y F C A R S V Y Y G G S Y Y F D Y W
--------J REGION-----(JH2)______120____
G 0 G T T L T V S S
GGC CAA GGC ACC ACT CTC ACA GTC TCC ICA
--- --- --- --- --- --- --- --- --- ---
FIGURE 1 .
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Sequences of the V regions of the antibodies expressed by hVH65-107 and
hVH65-110.Thesequences obtained arecompared to the nucleotide andamino acid sequences
of theV gene and its encoded protein produced by 36-65, a hybridoma that expresses the
canonical combination of V gene segments (see text) in germline form . Sequence identity is
indicated by adash (nucleotide sequence) or an asterisk (amino acid sequence) . Theendpoints
of data derived from amino acid sequence analysis are indicated by a slash . Nucleotide and/or
amino acid differences are shown explicitly . The one-letter code (21) is used to denote the
identity of amino acids . Nucleotide residues that could not be unambiguously identified are
indicated by N. Amino acid substitutions within regions analyzed by both nucleotide and
amino acid sequencing the identity of which was equivocal in the amino acid sequence analyses
are underlined . The location of sequences encoded by the D and Jx2 gene segments and
complementarity determining regions (CDR) are shown . These sequence data have been
submitted to the EMBL/GenBank Data Libraries under the accession number Y00637 .
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Vk SEQUENCES
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The sequences o£ the V, genesand their protein products expressed by hVH65-
110and hVH65-107 are displayed as described in Fig. 1 in comparison to thecomplete amino
acid sequence (M . N. Margolies, manuscript in preparation) and nucleotide sequence (22) of
the V, gene or protein expressed by 36-65 . The finding of cysteine at position 32 in the
hVH65-110 V, sequence was confirmed by amino acid sequence analysis of the hVH65-110
light chain after reduction and radioalkylation . These sequence data have been submitted to
theEMBL/GenBank Data Libraries under the accession number Y00637 .
combination-encoded antibodies (17, 18). Vjunctional positions 100 and 107
are characteristically variable among canonical combination-encoded Ars-bind-
ing V regions. The amino acids found at these positions in the hVH65-110 V
region have been previously observed to occur in several canonical combination-
encoded antibodies that have high affinity for Ars (14) ; those in the hVH65-107
V region have not .
While neither antibody binds detestably to Ars-BSA, lightly conjugated Ars-
KLH, or KLH alone, we could detect binding to highly conjugated preparations
ofArs-KLH . This allowed us to estimate the affinities of these antibodies relative
to 36-65 (Ka = 5 X 105/M) and several other high-affinity anti-Ars antibodies (Ka
of 106-10'/M) using a previously described plate binding assay (17) . The values
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obtained forrelative association constants in this waywere IOs/M for the hVH65-
107 V region and 104/M for the hVH65-110 V region .
Discussion
Several hypotheses might account for our ability to isolate, from mice undergo-
ing an anti-Ars response, hybridomas that express V regions the structures of
which are characteristic of a major high-affinity Ars-bindingV region but which
have extremely low affinity for Ars . First, theB cells expressing these antibodies
could have been stimulated by an antigen(s) unrelated to Ars . This seems highly
unlikely, since private idiotypic determinants characteristic of this V region
structure are not found in A/J nonimmune sera or in sera from A/J mice
immunized with antigens (e .g . KLH) other than Ars (18 andT . Manser, unpub-
lished data) . Second, the B cells expressing these low-affinity V regions could
have been stimulated at the onset of the anti-Ars response due to the high
concentration of antigen (200 jig) administered in adjuvant . This idea, however,
assumes that canonical combination-encoded, somatically mutated V region
structures preexist in the Ars-nonimmune B cell population . This assumption is
not supported by previous experiments indicating that most if not all somatic
mutation occurs during the antigen-dependent stages of B cell differentiation (6,
12) . Third, the B cells expressing these V regions may have been stimulated via
idiotype-antiidiotype network interactions that were induced by Ars immuniza-
tion but that are capable of Ars-independent B cell activation (e.g . stimulation
mediated by idiotype-specific T helper cells) . The fact that the two antibodies
we isolated express few of the idiotypic determinants characteristic of canonical
combination-encodedV regions and have low affinity for Ars does not support
this idea .
Finally, the hypothesis that is most consistent with our previous observations
is that random somatic mutations occur at a high rate in V genes during primary
clonal expansion, resulting in the generation of antigen-nonbinding V regions .
The B cells expressing such V regions may not continue to participate in the
response . However, these cells might be "rescued" as hybridomas if the fusion
event takes place soon after the "lethal" V region somatic mutation occurs . If
this assertion is correct, then the B cells that gave rise to hybridomas hVH65-
107 and hVH65-110 were directly clonally descended from cells that produced
antibodies with high affinity for Ars. The location of most of the productive
somatic mutations in the V genes expressed by these hybridomas in and around
complementarity-determining regions supports this idea . Interestingly, several
highly nonconservative mutational changes have occurred in these V regions
(e .g . in hVH65-110 V. : Tyr-32 to Cys, and Pro-40 to Ala; in hVH65-107 V :
Lys-38 to lie) . This latter class of mutations may be responsible for the Ars-
phenotype of theV regions these genes encode .
The two antibodies we have characterized apparently represent a new class of
antibody that is a by-product of the antigen-driven immune response . Further
isolation of antibodies of this type may provide new insights into the mechanisms
of regulation of V region expression during the immune response . In addition,
the study of such antibodies will undoubtedly help to further elucidate the effects
of somatic mutation on the structure and function of antibodyV domains .1462
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